PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Breast Cancer Res Treat. Author manuscript; available in PMC 2011 August 1.
Published in final edited form as:
PMCID: PMC2904403
NIHMSID: NIHMS192671

GPR30 and estrogen receptor expression: New insights into hormone dependence of inflammatory breast cancer

Abstract

Background

GPR30 is a novel G protein-coupled estrogen receptor (ER) associated with metastases in breast cancer (BC) and poor survival in endometrial and ovarian tumors. The association of GPR30 expression with inflammatory breast cancer (IBC), an aggressive and commonly hormone-independent form of BC, has not been studied.

Methods

GPR30, ER, progesterone receptor (PR), epidermal growth factor receptor (EGFR) and HER-2 expression were assessed by immunohistochemistry (and FISH for HER-2) in 88 primary IBCs. GPR30 expression was correlated with patient overall survival (OS), disease free survival (DFS), pathologic variables, and other biomarkers.

Results

GPR30 expression was found in 69% of IBC cases. ER, PR, HER-2 and EGFR were found in 43%, 35%, 39%, and 34% of IBC cases, respectively. GPR30 expression correlated inversely with ER expression (P=0.02). Co-expression of ER and GPR30 was found in 24% of IBC samples; 19% expressed only ER and 46% expressed only GPR30. Univariate analysis showed no association between GPR30 expression and OS or DFS. However, co-expression of ER and GPR30 was associated with improved OS (P<0.03) and marginally with DFS (P<0.06); the absence of both ER and GPR30 was associated with worse OS and DFS (P=0.03 for both). Multivariate analysis identified ER as an independent prognostic factor of OS (P=0.008) and DFS (P=0.02).

Conclusions

The majority of IBC tumors are GPR30-positive, suggesting that estrogen signaling may be active in ER-negative IBC patients. These findings suggest potential new therapeutic targets for IBC such as novel endocrine agents or direct modulation of GPR30.

Keywords: Inflammatory breast cancer, GPR30, Hormone receptors, growth factor receptors, overall survival, disease-free survival

Introduction

Inflammatory breast cancer (IBC) is a rare but aggressive and lethal form of breast cancer with clinical and biological characteristics of a rapidly proliferating disease [1, 2]. While the incidence of non-IBC (NIBC) has decreased based on the Surveillance, Epidemiology, and End Results (SEER) registries [3], that of IBC has increased throughout the 1990s [4]. IBC patients typically present with clinical signs mimicking an inflammatory process such as diffuse breast erythema, peau d’orange, skin induration, and warmth. Tumor emboli are often identified in dermal lymphatics, although these are not always seen on skin biopsy [2, 5]. Although multidisciplinary approaches and multimodality therapy, especially the administration of neoadjuvant chemotherapy, have improved the outcomes and survival rates for locally advanced breast cancer, the prognosis of IBC remains poor [6, 7]. This is in part related to the fact that knowledge of the molecular mechanism(s) underlying IBC still lags behind that of NIBC. At the molecular level, most IBC tumors are associated with features of poorer prognosis such as lack of hormone receptor expression, HER-2 amplification and over-expression of EGFR, nuclear factor kB (NF-kB), E-cadherin, and caveolin-1/2, as well as mutations of p53 [8, 9]. However, these markers are not specific for IBC. Although RhoC expression is considered a genetic determinant for IBC and coordinated changes in RhoC and WISP3 expression are fundamental to the pathogenesis of IBC [10], there are no useful clinical predictive markers in IBC. Therefore, elucidating the role of novel individual molecules and their associated pathways is important as they might provide insights into the biology of and potential new therapeutic targets for IBC.

GPR30, a recently characterized seven-transmembrane receptor belonging to the G-protein-coupled receptor family, binds estrogen with high affinity, and functions independently from the traditional nuclear estrogen receptors (ERα and ERβ) to regulate cellular and physiological responsiveness to estrogen [11, 12]. Activation of GPR30 leads to multiple intracellular responses related to growth, differentiation, and proliferation [13-15]. Therefore, GPR30-mediated activity is of particular interest for patients receiving hormone treatment since it may represent a new mechanism for resistance to classical endocrine therapy by allowing tumor cells to adapt to signaling pathways that can circumvent the classical ER-pathway [16]. Tamoxifen, an ER inhibitor widely used in the clinic, stimulates GPR30, which in turn trans-activates the EGFR signaling pathway [11, 13, 17]. This observation has led investigators to postulate that GPR30 modulates the effects of endocrine therapy by providing an alternative survival mechanism either directly or indirectly through cross-talk with growth receptors and other signaling molecules [18]. Furthermore, high expression of GPR30 in breast, endometrial and ovarian tumors has been associated with metastases and poor survival [19-21]. To define the role of GPR30 as a functional estrogen-related biomarker in IBC, we analyzed GPR30 expression in tissue samples of IBC patients that have completed neoadjuvant therapy and undergone surgery. We sought to evaluate the level of GPR30 expression, correlate it with the expression of hormone receptors, growth factors receptors and other known histopathological variables of IBC and assess the impact of expression on prognosis.

Methods

Clinical specimens

Eighty-eight patients with primary IBC who were treated at The University of Texas M. D. Anderson Cancer Center (MDACC) from September 1994 to August 2004 were included in this study. For the purposes of this study, patients were identified as having sufficient amount of residual tumor after neoadjuvant chemotherapy. Patients with pathological complete response, minimal residual tumor tissue, missing tissue or information were not included. This study was approved by the University of New Mexico Cancer Center (UNMCC) and MDACC Institutional Review Boards. Formalin-fixed paraffin-embedded tissues were obtained from mastectomy specimens and used to build tissue microarrays (TMAs) as described elsewhere [22]. This implies that all cases included had experienced clinical response to neoadjuvant chemotherapy but still displayed persistent disease at the time of surgery. IBC was diagnosed on the basis of clinical signs such as rapid progression (i.e., clinical evolution of less than 3 months) of diffuse skin erythema, peau d’orange, tenderness, induration, and warmth, with or without an underlying palpable mass, and a histologic proof of invasive breast carcinoma with or without evidence of dermal lymphatic invasion. The modified Black’s nuclear grading system was used to grade invasive tumor cells. All patients received multimodal treatment, including preoperative chemotherapy, surgery, and radiation therapy. The chemotherapy was given according to protocols described previously [23], consisting of four to six cycles of an anthracycline-based regimen that included doxorubicin (50 mg/m2), cyclophosphamide (500 mg/m2), and 5-fluorouracil (500 mg/m2) given every 21 days. The majority of the patients (89%) also received paclitaxel and 3 patients received trastuzumab. Endocrine therapy (Tamoxifen or aromatase inhibitor) was given to patients with ER-positive and/or PR-positive tumors.

Evaluation of ER, PR, HER-2, EGFR and GPR30 expression

ER, PR and HER-2 protein expression were determined by immunohistochemical staining (IHC) and HER-2 gene amplification was detected using fluorescent in situ hybridization (FISH) at MDACC; EGFR and GPR30 protein expression were assessed by IHC at UNMCC. When only limited tumor sample existed in the TMA core or the core tissue was lost during the IHC procedure, a whole section from the original block was used for the study.

ER, PR and HER2 expression levels were evaluated using standard procedures with the modified avidin–biotin complex method in a DAKO auto-stainer (DAKO, Carpinteria, CA) using primary antibodies against ER (clone 6F11; Novocastra, Burlingame, CA; Dilution, 1:50), PR (clone 1A6; Novocastra, Burlingame, CA; Dilution, 1:30) and HER-2 (clone AB8; Neomarker/Labvision Corporation, Fremont, CA; Dilution, 1:100) as previously described [24]. Normal endometrial (ER, PR) and breast (HER-2) tissues were used as positive controls; the same tissues, incubated with an isotype-matched antibody, were used as negative controls.

EGFR expression was detected with the 31G7 clone (Zymed, Carlsbad, CA; Dilution 1:50) using the Ventana XT Benchmark auto-stainer as described by the manufacturer (Ventana Medical Systems, Inc., Tucson, AZ). Briefly, tissue sections were baked, deparaffinized in xylene, rehydrated in graded ethanol (100% and 95%), and rinsed in water. The slides were then incubated in fresh 3% hydrogen peroxide in Dulbecco’s phosphate-buffered saline (DPBS: KCl/KH2PO4/NaCl/Na2HPO4-7H2O, 2.67/1.47/133.93/8.06 mM) for 20 min followed by three 5-min rinses in DPBS. The slides were loaded on to the Benchmark auto-stainer and detection was performed using the iVIEW™ DAB detection system (Ventana Medical Systems, Inc., Tucson, AZ).

GPR30 was detected as described elsewhere [20, 21] using a detection protocol similar to EGFR except that it was carried out manually; antibody retrieval was applied for 20 min in 10 mM citrate buffer (pH 6.0), and the incubation with an antibody against the GPR30 C-terminus was performed overnight. For both EGFR and GPR30 IHC assays, normal placenta was used as a positive control; normal placenta, incubated with an isotype-matched antibody was used as a negative control.

Detection of HER-2 gene copy number by fluorescent in situ hybridization (FISH)

FISH was performed as previously described [25] using the PathVysion HER-2 SpectrumOrange/CEP17 SpectrumGreen kit (Vysis, Downers Grove, IL).

Scoring of IHC results

Positive status for ER and PR was defined as having nuclear staining in at least 10% of invasive tumor cells. HER-2 positive status was defined as an IHC score of 3+ or a gene copy ratio of HER-2:CEP17 of ≥ 2.0. The tumors with an IHC score of 1+ or 2+ were confirmed by FISH.

For EGFR, signal intensity was scored as 0 (negative), 1+ (weak), 2+ (moderate), and 3+ (strong). Any complete membranous staining (>1+) was considered positive. The GPR30 protein levels were scored as previously described [21] using an H-scoring system obtained by multiplying the staining intensity (graded as 0 negative; 1+, weak; 2+, moderate and 3+, strong) by the percentage of epithelial tumor cells with GPR30-positive cytoplasmic staining (0 to 100%). The GPR30 cut-off was initially determined in 60 normal breast epithelial biopsies (8 biopsies from non-cancer patients and 52 histologically normal breast biopsies collected from a distant site of the invasive breast tumor biopsy of the same patient). The median obtained in the normal breast samples was selected as the cut-off, and for statistical analysis as well as to reduce observer variability, the samples were grouped into negative (H ≤ median) or positive (H > median) populations.

Statistical analysis

Primary outcomes for this study were overall survival (OS) and disease-free survival (DFS). OS was calculated from the date of diagnosis with death scored as an event and censoring of other patients at the date of last follow-up or of non-disease-related death. The DFS interval was calculated from the date of diagnosis to development of first recurrence. Patients without recurrence were censored at the time of last follow-up or death. Chi-square and Fisher’s exact tests were used to compare demographic, clinical, and pathological data between IBC patients and IHC results between samples. The Spearman test was used to assess correlations between GPR30 expression and ER, PR, HER2, and EGFR status. For the analysis of ER, PR, HER2, EGFR, and GPR30 status, patients were divided into two groups (positive and negative) as described above. OS and DFS for the groups defined by ER, PR, HER2, EGFR, and GPR30 status and other variables (age, nodal status, lymphovascular invasion, nuclear grade, and hormone treatment) were plotted using Kaplan–Meier curves and compared using the log-rank test. The Cox proportional hazard model with single covariates was used to obtain the hazard ratios (HRs) and associated 95% confidence intervals (CIs) for the groups compared. The primary multivariable analyses were performed using the Cox model, with adjustments made for age (<50, ≥ 50 years), number of positive nodes (≤ 3, ≥ 4), lymphovascular invasion (yes, no), nuclear grade (1, 2 vs. 3), hormone treatment (yes, no) and ER, PR, HER-2, EGFR and GPR30 status. Those variables found to be statistically significant in univariate analyses were considered for inclusion in the multivariate model. Inclusion was based on the significance of each variable as assessed by a likelihood ratio test comparing the multivariate model to the reduced model obtained by deleting variable(s) from the full model [26]. For each ordinal variable, the lowest value was used as the reference in computing hazard ratios (HR). Survival rates and HRs are presented with their 95% CIs. Wald tests were used to test for significance of HRs. Two-tailed P values less than 0.05 were considered statistically significant.

Results

Patient characteristics

Of the 88 patients included in this study, 84.1 % were non-Hispanic whites, 11.4% Hispanics, and 4.5% Blacks and Asians. The median age was 49.5 years (range, 23 to 75 years). The majority of cases were infiltrating ductal carcinomas (IDC; 88.6%), stage IIIB (76.1%), modified Black’s nuclear grade 3 (69.8%), with more than 4 positive nodes (63.8%) and positive for lymphovascular invasion (87.8%) at time of surgery, consistent with expectations for a cohort of patients at high risk of disease recurrence. Chemotherapy and hormone treatment were given to 95.5% and 35.6% of patients, respectively. The characteristics of patients and tumors are summarized in Table 1. The median follow-up interval was 45.7 months (range 0.2 to 164.2 months). At the time of analysis, 52 patients had died (61.2%); the OS was 48.6% and the DFS was 61.0% (Fig. 1).

Figure 1
Kaplan-Meier survival curves of OS (continuous line) and DFS (dotted line).
Table 1
Characteristics of the IBC samples

GPR30 expression in IBC samples

GPR30 was expressed in epithelial cells from normal breast biopsies (N=60; median H-score=125; range 0 to 300). In normal breast tissue, ductal and lobular epithelia displayed a cytoplasmic staining pattern with varying intensities (Fig. 2A and B). As in normal breast, IBC tissue exhibited a cytoplasmic staining pattern with staining intensity ranging from negative to strong (N=73; median H-score=160; range 0 to 300; P=0.043 for normal vs. IBC specimens; Fig. 2D-F). In several samples, staining of stromal tissue, inflammatory cells, myoepithelia and stromal fibroblasts was observed but neither was used in the grading scheme.

Figure 2
Representative IHC for GPR30 expression in IBC samples. Normal breast with negative (A) and strong (B) GPR30 expression. IBC cases with negative (D), moderate (E), and strong (F) GPR30 expression. Placenta (C) was used as a positive control and the inset ...

The majority of IBC cases were positive for GPR30 (68.5%, Table 1B). Approximately 24% of the tumors co-expressed ER and GPR30, 19% expressed only ER, 11% were negative for both ER and GPR30, and interestingly, GPR30 was expressed in 46% of tumors that failed to express ER (Table 1B). GPR30 expression was found to be inversely correlated with ER (P = 0.02), and hormone treatment but the latter association was not significant (P=0.11); GPR30 expression did not correlate with PR, EGFR or HER-2 (P > 0.1 for all) (data not shown).

ER, PR, EGFR, and HER-2 expression in IBC samples

The majority of samples were independently negative for ER, PR, HER-2, and EGFR. Fifty one percent of samples lacked expression of both ER and PR and 25% of the samples were “triple negative” (ER/PR/HER-2 negative) (Table 1B).

GPR30 expression and OS and DFS

GPR30 expression was not associated with OS or DFS (Fig. 3A, B and Supplemental Table 1). However, patients who were positive for GPR30 expression showed a higher median DFS as compared to the median DFS of the whole population (122 vs. 61 months, respectively)(See Fig. Fig.11 and and3B3B and Supplemental Table 1). Furthermore, co-expression of GPR30 and ER (GPR30/ER patterns) was associated with OS (P=0.033) but only marginally associated with DFS (P=0.057; Supplemental Table 1 and Supplemental Fig. 1A,B). In particular, tumors that expressed both GPR30 and ER showed a trend towards better OS and DFS than other expression patterns (Supplemental Table 1 and Supplemental Fig. 1A, B). Of note, patients showing no expression of both GPR30 and ER (GPR30/ER status) were associated with significantly decreased OS and DFS (P=0.03 for both; Supplemental Table 1 and Supplemental Fig. 2A, B).

Figure 3
Kaplan-Meier survival curves of OS (A) and DFS (B) time according to GPR30 expression. Dotted line represents GPR30-positive cases; continuous line, GPR30-negative IBC cases.

ER, PR, EGFR, HER-2 expression, clinical parameters and OS and DFS

ER expression was positively correlated with PR and hormone treatment (P<0.001 for both), and an inverse correlation was observed with EGFR (P<0.001) and HER-2 (P=0.02) expression. EGFR expression showed an inverse correlation with hormone treatment (P<0.05) but no correlation with HER-2 expression (P=0.60; Data not shown).

Of the clinico-pathological variables (age, number of positive nodes, lymphovascular invasion, nuclear grade, and hormone treatment) and biomarkers analyzed, hormone treatment, ER expression, and ER/PR expression patterns were associated with improved OS and DFS (Supplemental Table 1). Specifically, ER, either alone or co-expressed with PR, was significantly associated with an improved OS and DFS as shown by the Kaplan-Meier survival curves (Supplemental Table 1 and Supplemental. Fig. 3A, B).

“Triple negative status” was associated with poor OS and DFS (P<0.01 for both; Supplemental Table 1). The lack of GPR30 expression in these IBC cases was marginally associated with worse OS (P=0.06) but not with DFS (P=0.11; data not shown). Expression of EGFR was associated with decreased OS and DFS (P<0.05 for both; Supplemental Table 1).

Univariate and Multivariate analysis

In the univariate analysis, hormone treatment, ER expression, GPR30/ER patterns, GPR30/ER status, and ER/PR patterns were associated with improved OS and DFS (Table 2). Triple negative status and EGFR over-expression were associated with worse OS and DFS (Table 2). However, the multivariate analysis identified ER expression as the only independent prognostic factor associated with improved OS (HR=0.14; 95%CI 0.03 to 0.59; P=0.008) and DFS (HR=0.17; 95%CI 0.03 to 0.78; P=0.02) (Table 2).

Table 2
Univariate and multivariate analyses of OS and DFS

Discussion

IBC is an aggressive disease associated with resistance to standard multimodality therapy translating into a dismal prognosis [7]. The biological features of IBC have not been clearly defined but the disease is typically characterized by biomarkers of aggressive phenotypes such as high nuclear grade, lack of hormone receptor expression and HER-2 amplification [8-10]. Those characteristics have limited the use of treatment modalities otherwise effective in non-IBC, such as hormone treatment. Endocrine therapy has been employed in treatment and prevention of breast cancer and its efficacy is usually predicted on the basis of ER expression level. More recent research indicates a lack of concordance between tamoxifen responsiveness and ER expression [27], and suggests the existence of alternate routes critical for the growth and survival of breast cancer cells [16, 28]. GPR30 has been identified as an alternate route triggering activation of the EGFR and downstream molecules such as MAP kinases, as well as up-regulation of Bcl-2 and cyclin D2 [13-15]. We have previously shown that GPR30 is expressed in 48% of ovarian and 50% of endometrial tumors [20, 21]. In endometrial tumors, GPR30 expression is predictive of many parameters associated with adverse outcome (high grade and biologically aggressive histologic subtypes, cervical involvement, and advanced stage) and is associated with lower survival rates [20]. The same association with poor outcome is observed for GPR30 in ovarian cancer [21]. In non-IBC specimens, conflicting associations have been reported. In one study, GPR30 expression was shown to be a significant predictor of tumor size and metastases [19]. However, in a subsequent report, GPR30 expression was not associated with either HER-2 expression or survival [29]. While, the former study employed immunohistochemistry to assess GPR30 expression exclusively in epithelial tumor cells, the later investigation reported GPR30 expression from total RNA without isolating epithelial tumor cells. The use of different techniques may explain the discrepancies between the results of these two studies.

This study represents the first to investigate the role of GPR30 in relation to other known biomarkers and its impact on prognosis in IBC patients. While we found no association between GPR30 expression and outcome, it needs to be highlighted that the patients that were included in the study already had a dismal prognosis because they had extensive residual disease after neoadjuvant chemotherapy. The study confirmed the expression of hormone and growth factor receptors within the range of published data, indicating that the tumors analyzed in this study were representative of those included in other studies. Furthermore, we demonstrate several important biological correlations that may translate into significant clinical implications. First, we found that the majority (68.5%) of IBC tumors were GPR30-positive whereas ER was found in only 43% of tumors. There was no difference in incidence between the tumors that co-expressed ER and GPR30 (23.6%) and those ER-positive tumors that failed to express GPR30 (19.4%). However, twice as many (46%) of the ER-negative IBC tumors retained GPR30 (Table 1B), suggesting that ER and GPR30 expression in IBC is not interdependent and. One can further postulate that it may be possible to exploit novel endocrine therapies that work through non-classical estrogen-dependent pathways as potential therapies for IBC tumors despite the lack of detectable ER. Second, in contrast to NIBC [19], there was no correlation between GPR30 expression and HER-2 or between GPR30 and EGFR, as we previously observed in endometrial cancer [20]. These findings suggest that GPR30 may not use the EGFR and/or HER-2 routes as alternate pathways to promote tumor cell growth in IBC and/or it is possible that other yet unidentified routes may be activated by GPR30. Another explanation of these findings may lie in the intrinsic nature of IBC tumors, which are thought to be metastatic at the onset of the disease [8, 10] and, therefore, EGFR and/or HER-2 routes may not be critical or are bypassed in IBC tumors. This contrasts other studies performed in pre-clinical models and tissue specimens [19] and therefore required confirmatory studies. Third, we found that patients with GPR30 over-expression had prolonged disease control as documented by the fact the DFS was twice that of the studied population although it did not reach statistical significance. It should be noted that this result is opposite to what we have previously reported in endometrial and ovarian cancers, where GPR30 over-expression was a prognostic factor of poor survival [20, 21]. GPR30 over-expression seems to be associated with improved OS and DFS in ER-positive IBC patients, raising important biological questions related to the interplay between these two important receptors and their regulation of hormone-dependence in IBC.

Tamoxifen behaves as an agonist in GPR30-positive cells, resulting in activation of pro-survival signaling pathways such as ERK and PI3K/Akt [11, 13, 17]. Therefore, on one hand, this activation may be detrimental for GPR30-positive patients receiving tamoxifen. On the other hand, a brain tumor cell line model demonstrated that the biological effect of tamoxifen is dose-dependent with high doses of tamoxifen resulting in an increase of glioma cell apoptosis, suppression of tumor growth in vivo and improvement of survival in glioma xenograft models as a result of activation of pro-apoptotic genes, including NF-κB and its targets genes [30]. Furthermore, GPR30 over-expression inhibits urothelial cell proliferation as a result of decreased cyclin D1expression [31]. Given the protective effect of GPR30 expression observed in our study, we performed a subset analysis in our ER/PR-positive patients that received tamoxifen to analyze the effect of GPR30 expression in those patients. Although we found a trend for improved OS and DFS in GPR30-positive as compared to GPR30-negative patients, it did not reach statistical significance (data not shown) probably due to the small size of samples. Further analyses in a larger population are needed to confirm whether GPR30 may activate pro-apoptotic or anti-proliferative mechanisms that may result in a better response in ER/PR-positive patients treated with tamoxifen. Whether the same NF-κB or cyclin D pathways are activated in IBC patients remains unknown; ongoing studies in our group will clarify these associations.

A word of caution should be taken when analyzing these results: our study has the drawbacks inherent to retrospective studies and the small size of samples. Notwithstanding these limitations, the description by our group of a specific GPR30 agonist (G1) and antagonist (G15) [32, 33] fuels our enthusiasm to further assess the effects and mechanisms of action of both agents in IBC cell lines and tumor xenografts.

Supplementary Material

Supp FIg 2

Kaplan-Meier survival curves of OS (A) and (B) time according to GPR30/ER status.

Supp Fig 1

Kaplan-Meier survival curves of OS (A) and DFS (B) time according to GPR30/ER patterns.

Supp Fig 3

Kaplan-Meier survival curves of OS (A) and DFS (B) time according to ER status.

Supp Table I

Acknowledgements

Supported in part by NIH grant CA116662 (E.R.P.) and by New Mexico State IBC funding (New Mexico Senate Bill 532) and the State of Texas Inflammatory Breast Cancer Rider. We would like to thank the MDACC (Houston, TX) Human Tissue Repository for providing tissue samples and clinical data; Dr. A. Chakerian (EPL, Pathology, UNM) and T. Howard (Cell Biology and Physiology, UNM) for technical support with the IHC assays.

Footnotes

This work was partially presented at the First International Inflammatory Breast Cancer Conference (Houston, TX; December 5-7, 2008).

References

1. Levine PH, Veneroso C. The epidemiology of inflammatory breast cancer. Semin Oncol. 2008;35:11–16. [PubMed]
2. Singletary SE, Cristofanilli M. Defining the clinical diagnosis of inflammatory breast cancer. Semin Oncol. 2008;35:7–10. [PubMed]
3. Kerlikowske K, Miglioretti DL, Buist DSM, Walker R, Carney PA. Declines in Invasive Breast Cancer and Use of Postmenopausal Hormone Therapy in a Screening Mammography Population. J Natl Cancer Inst. 2007;99:1335–1339. [PubMed]
4. Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in Inflammatory Breast Carcinoma Incidence and Survival: The Surveillance, Epidemiology, and End Results Program at the National Cancer Institute. J Natl Cancer Inst. 2005;97:966–975. [PMC free article] [PubMed]
5. Molckovsky A, Fitzgerald B, Freedman O, Heisey R, Clemons M. Approach to inflammatory breast cancer. Can Fam Physician. 2009;55:25–31. [PMC free article] [PubMed]
6. Panades M, Olivotto IA, Speers CH, Shenkier T, Olivotto TA, Weir L, Allan SJ, Truong PT. Evolving Treatment Strategies for Inflammatory Breast Cancer: A Population-Based Survival Analysis. J Clin Oncol. 2005;23:1941–1950. [PubMed]
7. Dawood S, Ueno N, Cristofanilli M. The medical treatment of inflammatory breast cancer. Semin Oncol. 2008;35:64–71. [PubMed]
8. Charafe-Jauffret E, Tarpin C, Viens P, Bertucci F. Defining the molecular biology of inflammatory breast cancer. Semin Oncol. 2008;35:41–50. [PubMed]
9. Gong Y. Pathologic Aspects of Inflammatory Breast Cancer: Part 2. Biologic Insights Into Its Aggressive Phenotype. Seminars in Oncology. 2008;35:33–40. [PubMed]
10. Ventura AC, Merajver SD. Genetic determinants of aggressive breast cancer. Annu Rev Med. 2008;59:199–212. [PubMed]
11. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A Transmembrane Intracellular Estrogen Receptor Mediates Rapid Cell Signaling. Science. 2005;307:1625–1630. [PubMed]
12. Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an Estrogen Membrane Receptor Coupled to a G Protein in Human Breast Cancer Cells. Endocrinology. 2005;146:624–632. [PubMed]
13. Filardo EJ, Quinn JA, Bland KI, Frackelton AR., Jr. Estrogen-Induced Activation of Erk-1 and Erk-2 Requires the G Protein-Coupled Receptor Homolog, GPR30, and Occurs via Trans-Activation of the Epidermal Growth Factor Receptor through Release of HB-EGF. Mol Endocrinol. 2000;14:1649–1660. [PubMed]
14. Kanda N, Watanabe S. 17beta-estradiol inhibits oxidative stress-induced apoptosis in keratinocytes by promoting Bcl-2 expression. J Invest Dermatol. 2003;121:1500–1509. [PubMed]
15. Kanda N, Watanabe S. 17beta-estradiol stimulates the growth of human keratinocytes by inducing cyclin D2 expression. J Invest Dermatol. 2004;123:319–328. [PubMed]
16. Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA, Hathaway HJ. Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu Rev Physiol. 2008;70:165–190. [PubMed]
17. Filardo EJ, Quinn JA, Frackelton AR, Jr., Bland KI. Estrogen Action Via the G Protein-Coupled Receptor, GPR30: Stimulation of Adenylyl Cyclase and cAMP-Mediated Attenuation of the Epidermal Growth Factor Receptor-to-MAPK Signaling Axis. Mol Endocrinol. 2002;16:70–84. [PubMed]
18. Prossnitz ER, Sklar LA, Oprea TI, Arterburn JB. GPR30: a novel therapeutic target in estrogen-related disease. Trends Pharmacol Sci. 2008;29:116–123. [PubMed]
19. Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, Steinhoff MM, Sabo E. Distribution of GPR30, a Seven Membrane-Spanning Estrogen Receptor, in Primary Breast Cancer and its Association with Clinicopathologic Determinants of Tumor Progression. Clin Cancer Res. 2006;12:6359–6366. [PubMed]
20. Smith HA, Leslie K, Singh M, Qualls CR, Revankar CM, Joste N, Prossnitz ER. GPR-30: a novel indicator of poor survival in endometrial carcinoma. Am J Obstet Gynecol. 2007;196:386.e381–389. [PubMed]
21. Smith H, Arias-Pulido H, Kuo D, Howard T, Qualls C, Lee S-J, Verschraegen C, Hathaway H, Joste N, Prossnitz E. GPR30 predicts poor survival for ovarian cancer. Gyn Oncol. 2009;114:465–471. [PMC free article] [PubMed]
22. Ginestier C, Charafe-Jauffret E, Bertucci F, Eisinger F, Geneix J, Bechlian D, Conte N, Adelaide J, Toiron Y, Nguyen C, et al. Distinct and Complementary Information Provided by Use of Tissue and DNA Microarrays in the Study of Breast Tumor Markers. Am J Pathol. 2002;161:1223–1233. [PubMed]
23. Cristofanilli M, Buzdar AU, Hortobagyi GN. Update on the Management of Inflammatory Breast Cancer. Oncologist. 2003;8:141–148. [PubMed]
24. Cabioglu N, Gong Y, Islam R, Broglio KR, Sneige N, Sahin A, Gonzalez-Angulo AM, Morandi P, Bucana C, Hortobagyi GN, et al. Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann Onc. 2007;18:1021–1029. [PubMed]
25. Gong Y, Booser D, Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer. 2005;103:1763–1769. [PubMed]
26. Lachin J. Biostatistical Methods. John Wiley and Sons; NY: 2000. pp. 272–285.
27. EBCTCG Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet. 2005;365:1687–1717. [PubMed]
28. Filardo EJ, Thomas P. GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol Metab. 2005;16:362–367. [PubMed]
29. Kuo W, Chang L, Liu D, Hwa H, Lin J, Lee P, Chen C, Lien H, Yuan R, Shun C, et al. The interactions between GPR30 and the major biomarkers in infiltrating ductal carcinoma of the breast in an Asian population. Taiwan J Obstet Gynecol. 2007;46:135–145. [PubMed]
30. Hui A-M, Zhang W, Chen W, Xi D, Purow B, Friedman GC, Fine HA. Agents with Selective Estrogen Receptor (ER) Modulator Activity Induce Apoptosis In vitro and In vivo in ER-Negative Glioma Cells. Cancer Res. 2004;64:9115–9123. [PubMed]
31. Teng J, Wang Z-Y, Prossnitz ER, Bjorling DE. The G Protein-Coupled Receptor GPR30 Inhibits Human Urothelial Cell Proliferation. Endocrinology. 2008;149:4024–4034. [PubMed]
32. Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS, Parker MA, Tkachenko SE, Savchuck NP, Sklar LA, et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol. 2006;2:207–212. [PubMed]
33. Dennis M, Burai R, Ramesh C, Petrie W, Alcon S, Nayak T, Bologa C, Leitao A, Brailoiu E, Deliu E, et al. In vivo effects of a GPR30 antagonist. Nat Chem Biol. 2009;5:421–427. [PMC free article] [PubMed]